Seite auf Deutsch Fibrosis

Tissue transglutaminase (TG2) plays a central role in fibrosis by recruiting TGF-β, disturbing extracellular matrix protein homeostasis, and supporting fibroblast proliferation.
Zedira scientists developed a new class of tissue transglutaminase inhibitors with a reversible mode-of-inhibition that are potent and selective. The novel compounds were optimized for in vivo oral bioavailability and favorable pharmacokinetic profiles. Please refer to the respective press release.

Proprietary drug candidates are therefore available to target dysregulated active TG2 in fibrotic disorders of the lung, kidney, and liver. Zedira offers partnerships for the clinical development of these drug candidates.

In July 2022, Dr. Falk Pharma and Zedira announced the start of the phase 2a proof-of-concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD) (press release).

Moreover, Zedira is planning to expand its global leadership position in the transglutaminase field by investing in follow-up drug discovery projects.

Interested? Please, do not hesitate to contact us: